SanBio Company Limited [4592.T]
TOKYO, Apr 23 (Pulse News Wire) – Sanbio Company Limited (4592.T) reported robust financial results for the fiscal year ending January 31, 2026, with a lower net profit of ¥149.72 million compared to ¥152.40 million in the previous year. Research and development expenses amounted to ¥3.794 billion, down from ¥4.121 billion last year.
The company secured significant funds through overseas share issuance on July 31, 2024, raising approximately ¥1.489 billion. Proceeds will support domestic promotion of ACTOGO®, phase three clinical trials for traumatic brain injury (TBI) in the United States, and domestic stroke development activities.
Additionally, SanBio entered into commitment lines with major banks, totaling ¥1.482 billion, aimed at building manufacturing, logistics, and sales infrastructure for ACTOGO®. Looking ahead, SanBio projects continued investment in research and development, anticipating expenditures of ¥3.8 billion for the fiscal year ending January 31, 2027.
The company expects to achieve positive operating profit in the next fiscal year, driven by increased revenue from ACTOGO® commercialization and ongoing clinical trial advancements.
🟡 Confidence: Standard AI-translated content.